---
schema_version: "secwatch.filing_event.v1"
accession: "0000920148-23-000023"
form_type: "8-K"
ticker: "LH"
cik: "0000920148"
company_name: "LABCORP HOLDINGS INC."
filed_at: "2023-04-25T23:59:59+00:00"
generated_at: "2026-06-16T18:05:12.003037+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Labcorp Q1 revenue down 3.1% to $3.78B; adj EPS $3.82 vs $6.11; guides FY adj EPS $16.25-$17.75

## Summary
- Q1 revenue $3.78B vs $3.90B prior year; Base Business organic growth +7.9% offset by COVID-19 Testing decline -11.6%.
- Diluted EPS $2.39, adjusted EPS $3.82; prior year $5.23 and $6.11 respectively; free cash flow $27M vs $239M.
- FY2023 guidance: adjusted EPS narrowed to $16.25-$17.75 (midpoint unchanged), free cash flow $1.0B-$1.2B.
- Diagnostics adj op income $441.5M (18.5% margin) down from $683.1M (27.8%); Drug Development adj op income $123.9M (8.8%) down from $168.6M (11.6%).
- Spin of Clinical Development (Fortrea) on track for mid-2023; quarterly dividend $0.72/share payable June 8, 2023.

## SEC filing metadata
- accession: 0000920148-23-000023
- form_type: 8-K
- ticker: LH
- cik: 0000920148
- company_name: LABCORP HOLDINGS INC.
- filed_at: 2023-04-25T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/920148/000092014823000023/0000920148-23-000023-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/920148/000092014823000023/lh-20230425.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000920148-23-000023
- JSON: https://secwatch.observer/filing/0000920148-23-000023.json
- Plain text: https://secwatch.observer/filing/0000920148-23-000023.txt

## Key facts
- Earnings Releases
  LABCORP HOLDINGS INC. updated its full-year 2023 guidance (reaffirmed).
  - Period: full-year 2023
  - Guidance: reaffirmed
  - Result: guidance update
  source text: • Full-Year 2023 Guidance: Adjusted EPS narrowed to $16.25 to $17.75 with midpoint unchanged and Free Cash Flow remains at $1.0 billion to $1.2 billion
  evidence_url: https://www.sec.gov/Archives/edgar/data/920148/000092014823000023/0000920148-23-000023-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.